TELA Bio, Inc. (TELA) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$9.28M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$10.53M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$7.55M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$9.08M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$9.28M | (m) | $19.29M | (m) | $59.00K* | -$9.38M* | (m) | $2.72M | (m) | $60.00K |
| 2026-03-31 | Reported | (m) | -$10.53M | (m) | $19.06M | (m) | $119.00K | -$11.17M | (m) | $2.34M | (m) | $60.00K |
| 2025-09-30 | Reported | (m) | -$7.55M | (m) | $20.69M | (m) | $211.00K* | -$5.72M* | (m) | $2.35M | (m) | $0.00* |
| 2025-06-30 | Reported | (m) | -$9.08M | (m) | $20.20M | (m) | $114.00K* | -$7.91M* | (m) | $2.20M | (m) | $33.00K |
| 2025-03-31 | Reported | (m) | -$10.47M | (m) | $18.52M | (m) | $32.00K | -$9.72M | (m) | $2.54M | (m) | $52.00K |
| 2024-09-30 | Reported | (m) | -$9.37M | (m) | $18.96M | (m) | $122.00K* | -$8.98M* | (m) | $2.07M | (m) | (m) |
| 2024-06-30 | Reported | (m) | -$11.57M | (m) | $16.09M | (m) | $299.00K* | -$10.70M* | (m) | $2.32M | (m) | (m) |
| 2024-03-31 | Reported | (m) | -$4.83M | (m) | $16.60M | (m) | $304.00K | -$14.38M | (m) | $2.39M | (m) | (m) |
| 2023-09-30 | Reported | (m) | -$10.18M | (m) | $15.05M | (m) | $134.00K* | -$6.97M* | (m) | $2.37M | (m) | (m) |
| 2023-06-30 | Reported | (m) | -$10.36M | (m) | $14.49M | (m) | $157.00K* | -$11.26M* | (m) | $2.51M | (m) | (m) |
| 2023-03-31 | Reported | (m) | -$11.25M | (m) | $11.91M | (m) | $115.00K | -$11.57M | (m) | $2.05M | (m) | (m) |
| 2022-09-30 | Reported | (m) | -$9.49M | (m) | $11.16M | (m) | $290.00K* | -$7.65M* | (m) | $2.10M | (m) | (m) |
| 2022-06-30 | Reported | (m) | -$10.24M | (m) | $10.41M | (m) | $200.00K* | -$11.69M* | (m) | $2.10M | (m) | (m) |
| 2022-03-31 | Reported | (m) | -$9.84M | (m) | $8.23M | (m) | $336.00K | -$10.43M | (m) | $2.01M | (m) | (m) |
| 2021-09-30 | Reported | (m) | -$7.22M | (m) | $7.65M | (m) | $291.00K* | -$6.63M* | (m) | $1.41M | (m) | (m) |
| 2021-06-30 | Reported | (m) | -$7.31M | (m) | $7.56M | (m) | $25.00K* | -$5.63M* | (m) | $1.93M | (m) | (m) |
| 2021-03-31 | Reported | (m) | -$7.27M | (m) | $5.88M | (m) | $22.00K | -$8.59M | (m) | $1.68M | (m) | (m) |
| 2020-09-30 | Reported | (m) | -$6.86M | (m) | $5.31M | (m) | $33.00K* | -$3.69M* | (m) | $1.20M | (m) | (m) |
| 2020-06-30 | Reported | (m) | -$5.17M | (m) | $3.51M | (m) | $28.00K* | -$6.36M* | (m) | $979.00K | (m) | (m) |
| 2020-03-31 | Reported | (m) | -$6.50M | (m) | $3.73M | (m) | $68.00K | -$7.31M | (m) | $912.00K | (m) | (m) |
| 2019-09-30 | Reported | (m) | -$3.86M | (m) | $3.97M | (m) | $75.00K* | -$5.36M* | (m) | $516.00K | (m) | (m) |
| 2019-06-30 | Reported | (m) | -$4.30M | (m) | $3.30M | (m) | $41.00K* | -$5.21M* | (m) | $1.05M | (m) | (m) |
| 2019-03-31 | Reported | (m) | -$5.18M | (m) | $3.31M | (m) | $48.00K | -$7.78M | (m) | $1.66M | (m) | (m) |
| 2018-09-30 | Reported | (m) | -$2.52M | (m) | $2.21M | (m) | (m) | (m) | (m) | $1.04M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$33.76M | (m) | $80.28M | (m) | $448.00K | -$28.22M | (m) | $9.22M | (m) | $230.00K |
| 2024-12-31 | Reported | (m) | -$34.12M | (m) | $69.30M | (m) | $989.00K | -$41.59M | (m) | $8.81M | (m) | -$144.00K |
| 2023-12-31 | Reported | (m) | -$44.08M | (m) | $58.45M | (m) | $611.00K | -$40.86M | (m) | $9.62M | (m) | (m) |
| 2022-12-31 | Reported | (m) | -$39.01M | (m) | $41.42M | (m) | $872.00K | -$40.75M | (m) | $8.94M | (m) | (m) |
| 2021-12-31 | Reported | (m) | -$29.45M | (m) | $29.46M | (m) | $627.00K | -$30.43M | (m) | $6.74M | (m) | (m) |
| 2020-12-31 | Reported | (m) | -$25.27M | (m) | $18.21M | (m) | $167.00K | -$24.46M | (m) | $4.25M | (m) | (m) |
| 2019-12-31 | Reported | (m) | -$19.16M | (m) | $15.45M | (m) | $197.00K | -$25.52M | (m) | $4.15M | (m) | (m) |
| 2018-12-31 | Reported | (m) | -$17.78M | (m) | $8.27M | (m) | $62.00K | -$19.92M | (m) | $4.34M | (m) | (m) |
| 2017-12-31 | Reported | (m) | -$16.92M | (m) | $4.25M | (m) | $114.00K | -$16.37M | (m) | $5.79M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B | |
| Spectral AI, Inc. (MDAI) | United States | $0.052B | |
| Sensus Healthcare, Inc. (SRTS) | United States | $0.048B | -3.24 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 | |
| CVRx, Inc. (CVRX) | United States | $0.067B | -2.62 |
| NEPHROS INC (NEPH) | United States | $0.046B | 23.02 |
| SANUWAVE Health, Inc. (SNWV) | United States | $0.041B | 5.47 |
| FRACTYL HEALTH, INC. (GUTS) | United States | $0.075B | -1.18 |
| RenovoRx, Inc. (RNXT) | United States | $0.076B | -3.62 |
| InspireMD, Inc. (NSPR) | $0.033B |